ASGE guideline on the management of cholangitis

James L. Buxbaum; Carlos Buitrago; Alice Lee; Badih Joseph Elmunzer; Ahsun Riaz; Eugene P. Ceppa; Mohammed Al-Haddad; Stuart K. Amateau; Audrey H. Calderwood; Douglas S. Fishman; Larissa L. Fujii-Lau; Laith H. Jamil; Terry L. Jue; Richard S. Kwon; Joanna K. Law; Jeffrey K. Lee; Mariam Naveed; Swati Pawa; Mandeep S. Sawhney; Hannah Schilperoort; Andrew C. Storm; Nirav C. Thosani; Bashar J. Qumseya; Sachin Wani

doi:10.1016/j.gie.2020.12.032

ASGE guideline on the management of cholangitis

James L. Buxbaum, Carlos Buitrago, Alice Lee, Badih Joseph Elmunzer, Ahsun Riaz, Eugene P. Ceppa, Mohammed Al-Haddad, Stuart K. Amateau, Audrey H. Calderwood, Douglas S. Fishman, Larissa L. Fujii-Lau, Laith H. Jamil, Terry L. Jue, Richard S. Kwon, Joanna K. Law, Jeffrey K. Lee, Mariam Naveed, Swati Pawa, Mandeep S. Sawhney, Hannah SchilperoortAndrew C. Storm, Nirav C. Thosani, Bashar J. Qumseya, Sachin Wani

Medicine - Gastro, Hepatology, Nutrition Division

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Cholangitis is a GI emergency requiring prompt recognition and treatment. The purpose of this document from the American Society for Gastrointestinal Endoscopy's (ASGE) Standards of Practice Committee is to provide an evidence-based approach for management of cholangitis. This document addresses the modality of drainage (endoscopic vs percutaneous), timing of intervention (<48 hours vs >48 hours), and extent of initial intervention (comprehensive therapy vs decompression alone). Grading of Recommendations, Assessment, Development, and Evaluation methodology was used to formulate recommendations on these topics. The ASGE suggests endoscopic rather than percutaneous drainage and biliary decompression within 48 hours. Additionally, the panel suggests that sphincterotomy and stone removal be combined with drainage rather than decompression alone, unless patients are too unstable to tolerate more extensive endoscopic treatment.

Original language	English (US)
Pages (from-to)	207-221.e14
Journal	Gastrointestinal endoscopy
Volume	94
Issue number	2
DOIs	https://doi.org/10.1016/j.gie.2020.12.032
State	Published - Aug 1 2021

Bibliographical note

Funding Information:
The following authors disclosed financial relationships: J. Buxbaum is a consultant for Boston Scientific Corporation, Eagle Pharmaceuticals, Inc, Cook Medical LLC, and Olympus America Inc; and receives grant support from Medtronic USA, Inc and Olympus America Inc. C. Buitrago disclosed no financial relationships. A. Lee disclosed no financial relationships. B. Elmunzer is a consultant for Takeda Pharmaceuticals. A. Riaz disclosed no financial relationships. E. Ceppa disclosed no financial relationships . M. Al-Haddad has received research and teaching support from Boston Scientific Corporation. S. Amateau is a consultant for Boston Scientific Corporation, Cook Medical LLC, Endo-Therapeutics, Hemostasis LLC, Merit Medical Systems Inc, Olympus Corporation of the Americas, and STERIS Corporation. A. Calderwood disclosed no financial relationships. D. Fishman disclosed no financial relationships. L. Fujii-Lau has received travel compensation from Ovesco. L. Jamil disclosed no financial relationships. T. Jue disclosed no financial relationships. R. Kwon disclosed no financial relationships. J. Law disclosed no financial relationships. J. Lee disclosed no financial relationships. M. Naveed disclosed no financial relationships. S. Pawa disclosed no financial relationships. M. Sawhney is a stock holder with Allurion Technology, Inc, H. Schilperoort disclosed no financial relationships. A. Storm is a consultant for Apollo Endo Surgery, Endo-TAGSS, and Enterasense; data and safety monitoring from ERBE USA Inc and GI Dynamics; and receives research support from Boston Scientific. N. Thosani is a consultant for Boston Scientific Coporation, TaeWoong Medical, is a consultant and receives research support from PENTAX of America, Inc, receives royalties from UpToDate, receives research support from Endogastric Solutions, is a speaker for Abbie, and is on the advisory board for ColubrisMX Inc. B. Qumseya disclosed no financial relationships. S. Wani is a consultant for Boston Scientific Corporation, Medtronic, Exact Sciences and Interpace, and is on the advisory board for Cernostics.

Funding Information:
The authors are grateful to Patricia Maxin from the Cholangiocarcinoma Foundation for her input as a patient advocate on this guideline panel. This guideline was funded exclusively by the American Society for Gastrointestinal Endoscopy; no outside funding was received to support the development of this guideline.

Publisher Copyright:
© 2021 American Society for Gastrointestinal Endoscopy

PubMed: MeSH publication types

Practice Guideline

Publisher link

10.1016/j.gie.2020.12.032

Find It

Find It at U of M Libraries

Cite this

Buxbaum, J. L., Buitrago, C., Lee, A., Elmunzer, B. J., Riaz, A., Ceppa, E. P., Al-Haddad, M., Amateau, S. K., Calderwood, A. H., Fishman, D. S., Fujii-Lau, L. L., Jamil, L. H., Jue, T. L., Kwon, R. S., Law, J. K., Lee, J. K., Naveed, M., Pawa, S., Sawhney, M. S., ... Wani, S. (2021). ASGE guideline on the management of cholangitis. Gastrointestinal endoscopy, 94(2), 207-221.e14. https://doi.org/10.1016/j.gie.2020.12.032

Buxbaum, JL, Buitrago, C, Lee, A, Elmunzer, BJ, Riaz, A, Ceppa, EP, Al-Haddad, M, Amateau, SK, Calderwood, AH, Fishman, DS, Fujii-Lau, LL, Jamil, LH, Jue, TL, Kwon, RS, Law, JK, Lee, JK, Naveed, M, Pawa, S, Sawhney, MS, Schilperoort, H, Storm, AC, Thosani, NC, Qumseya, BJ & Wani, S 2021, 'ASGE guideline on the management of cholangitis', Gastrointestinal endoscopy, vol. 94, no. 2, pp. 207-221.e14. https://doi.org/10.1016/j.gie.2020.12.032

@article{bea782113fc04623b2c3a1b7e9f49267,

title = "ASGE guideline on the management of cholangitis",

abstract = "Cholangitis is a GI emergency requiring prompt recognition and treatment. The purpose of this document from the American Society for Gastrointestinal Endoscopy's (ASGE) Standards of Practice Committee is to provide an evidence-based approach for management of cholangitis. This document addresses the modality of drainage (endoscopic vs percutaneous), timing of intervention (<48 hours vs >48 hours), and extent of initial intervention (comprehensive therapy vs decompression alone). Grading of Recommendations, Assessment, Development, and Evaluation methodology was used to formulate recommendations on these topics. The ASGE suggests endoscopic rather than percutaneous drainage and biliary decompression within 48 hours. Additionally, the panel suggests that sphincterotomy and stone removal be combined with drainage rather than decompression alone, unless patients are too unstable to tolerate more extensive endoscopic treatment.",

author = "Buxbaum, {James L.} and Carlos Buitrago and Alice Lee and Elmunzer, {Badih Joseph} and Ahsun Riaz and Ceppa, {Eugene P.} and Mohammed Al-Haddad and Amateau, {Stuart K.} and Calderwood, {Audrey H.} and Fishman, {Douglas S.} and Fujii-Lau, {Larissa L.} and Jamil, {Laith H.} and Jue, {Terry L.} and Kwon, {Richard S.} and Law, {Joanna K.} and Lee, {Jeffrey K.} and Mariam Naveed and Swati Pawa and Sawhney, {Mandeep S.} and Hannah Schilperoort and Storm, {Andrew C.} and Thosani, {Nirav C.} and Qumseya, {Bashar J.} and Sachin Wani",

note = "Funding Information: The following authors disclosed financial relationships: J. Buxbaum is a consultant for Boston Scientific Corporation, Eagle Pharmaceuticals, Inc, Cook Medical LLC, and Olympus America Inc; and receives grant support from Medtronic USA, Inc and Olympus America Inc. C. Buitrago disclosed no financial relationships. A. Lee disclosed no financial relationships. B. Elmunzer is a consultant for Takeda Pharmaceuticals. A. Riaz disclosed no financial relationships. E. Ceppa disclosed no financial relationships . M. Al-Haddad has received research and teaching support from Boston Scientific Corporation. S. Amateau is a consultant for Boston Scientific Corporation, Cook Medical LLC, Endo-Therapeutics, Hemostasis LLC, Merit Medical Systems Inc, Olympus Corporation of the Americas, and STERIS Corporation. A. Calderwood disclosed no financial relationships. D. Fishman disclosed no financial relationships. L. Fujii-Lau has received travel compensation from Ovesco. L. Jamil disclosed no financial relationships. T. Jue disclosed no financial relationships. R. Kwon disclosed no financial relationships. J. Law disclosed no financial relationships. J. Lee disclosed no financial relationships. M. Naveed disclosed no financial relationships. S. Pawa disclosed no financial relationships. M. Sawhney is a stock holder with Allurion Technology, Inc, H. Schilperoort disclosed no financial relationships. A. Storm is a consultant for Apollo Endo Surgery, Endo-TAGSS, and Enterasense; data and safety monitoring from ERBE USA Inc and GI Dynamics; and receives research support from Boston Scientific. N. Thosani is a consultant for Boston Scientific Coporation, TaeWoong Medical, is a consultant and receives research support from PENTAX of America, Inc, receives royalties from UpToDate, receives research support from Endogastric Solutions, is a speaker for Abbie, and is on the advisory board for ColubrisMX Inc. B. Qumseya disclosed no financial relationships. S. Wani is a consultant for Boston Scientific Corporation, Medtronic, Exact Sciences and Interpace, and is on the advisory board for Cernostics. Funding Information: The authors are grateful to Patricia Maxin from the Cholangiocarcinoma Foundation for her input as a patient advocate on this guideline panel. This guideline was funded exclusively by the American Society for Gastrointestinal Endoscopy; no outside funding was received to support the development of this guideline. Publisher Copyright: {\textcopyright} 2021 American Society for Gastrointestinal Endoscopy",

year = "2021",

month = aug,

day = "1",

doi = "10.1016/j.gie.2020.12.032",

language = "English (US)",

volume = "94",

pages = "207--221.e14",

journal = "Gastrointestinal Endoscopy",

issn = "0016-5107",

publisher = "Mosby Inc.",

number = "2",

}

TY - JOUR

T1 - ASGE guideline on the management of cholangitis

AU - Buxbaum, James L.

AU - Buitrago, Carlos

AU - Lee, Alice

AU - Elmunzer, Badih Joseph

AU - Riaz, Ahsun

AU - Ceppa, Eugene P.

AU - Al-Haddad, Mohammed

AU - Amateau, Stuart K.

AU - Calderwood, Audrey H.

AU - Fishman, Douglas S.

AU - Fujii-Lau, Larissa L.

AU - Jamil, Laith H.

AU - Jue, Terry L.

AU - Kwon, Richard S.

AU - Law, Joanna K.

AU - Lee, Jeffrey K.

AU - Naveed, Mariam

AU - Pawa, Swati

AU - Sawhney, Mandeep S.

AU - Schilperoort, Hannah

AU - Storm, Andrew C.

AU - Thosani, Nirav C.

AU - Qumseya, Bashar J.

AU - Wani, Sachin

N1 - Funding Information: The following authors disclosed financial relationships: J. Buxbaum is a consultant for Boston Scientific Corporation, Eagle Pharmaceuticals, Inc, Cook Medical LLC, and Olympus America Inc; and receives grant support from Medtronic USA, Inc and Olympus America Inc. C. Buitrago disclosed no financial relationships. A. Lee disclosed no financial relationships. B. Elmunzer is a consultant for Takeda Pharmaceuticals. A. Riaz disclosed no financial relationships. E. Ceppa disclosed no financial relationships . M. Al-Haddad has received research and teaching support from Boston Scientific Corporation. S. Amateau is a consultant for Boston Scientific Corporation, Cook Medical LLC, Endo-Therapeutics, Hemostasis LLC, Merit Medical Systems Inc, Olympus Corporation of the Americas, and STERIS Corporation. A. Calderwood disclosed no financial relationships. D. Fishman disclosed no financial relationships. L. Fujii-Lau has received travel compensation from Ovesco. L. Jamil disclosed no financial relationships. T. Jue disclosed no financial relationships. R. Kwon disclosed no financial relationships. J. Law disclosed no financial relationships. J. Lee disclosed no financial relationships. M. Naveed disclosed no financial relationships. S. Pawa disclosed no financial relationships. M. Sawhney is a stock holder with Allurion Technology, Inc, H. Schilperoort disclosed no financial relationships. A. Storm is a consultant for Apollo Endo Surgery, Endo-TAGSS, and Enterasense; data and safety monitoring from ERBE USA Inc and GI Dynamics; and receives research support from Boston Scientific. N. Thosani is a consultant for Boston Scientific Coporation, TaeWoong Medical, is a consultant and receives research support from PENTAX of America, Inc, receives royalties from UpToDate, receives research support from Endogastric Solutions, is a speaker for Abbie, and is on the advisory board for ColubrisMX Inc. B. Qumseya disclosed no financial relationships. S. Wani is a consultant for Boston Scientific Corporation, Medtronic, Exact Sciences and Interpace, and is on the advisory board for Cernostics. Funding Information: The authors are grateful to Patricia Maxin from the Cholangiocarcinoma Foundation for her input as a patient advocate on this guideline panel. This guideline was funded exclusively by the American Society for Gastrointestinal Endoscopy; no outside funding was received to support the development of this guideline. Publisher Copyright: © 2021 American Society for Gastrointestinal Endoscopy

PY - 2021/8/1

Y1 - 2021/8/1

N2 - Cholangitis is a GI emergency requiring prompt recognition and treatment. The purpose of this document from the American Society for Gastrointestinal Endoscopy's (ASGE) Standards of Practice Committee is to provide an evidence-based approach for management of cholangitis. This document addresses the modality of drainage (endoscopic vs percutaneous), timing of intervention (<48 hours vs >48 hours), and extent of initial intervention (comprehensive therapy vs decompression alone). Grading of Recommendations, Assessment, Development, and Evaluation methodology was used to formulate recommendations on these topics. The ASGE suggests endoscopic rather than percutaneous drainage and biliary decompression within 48 hours. Additionally, the panel suggests that sphincterotomy and stone removal be combined with drainage rather than decompression alone, unless patients are too unstable to tolerate more extensive endoscopic treatment.

AB - Cholangitis is a GI emergency requiring prompt recognition and treatment. The purpose of this document from the American Society for Gastrointestinal Endoscopy's (ASGE) Standards of Practice Committee is to provide an evidence-based approach for management of cholangitis. This document addresses the modality of drainage (endoscopic vs percutaneous), timing of intervention (<48 hours vs >48 hours), and extent of initial intervention (comprehensive therapy vs decompression alone). Grading of Recommendations, Assessment, Development, and Evaluation methodology was used to formulate recommendations on these topics. The ASGE suggests endoscopic rather than percutaneous drainage and biliary decompression within 48 hours. Additionally, the panel suggests that sphincterotomy and stone removal be combined with drainage rather than decompression alone, unless patients are too unstable to tolerate more extensive endoscopic treatment.

UR - http://www.scopus.com/inward/record.url?scp=85106369045&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85106369045&partnerID=8YFLogxK

U2 - 10.1016/j.gie.2020.12.032

DO - 10.1016/j.gie.2020.12.032

M3 - Article

C2 - 34023065

AN - SCOPUS:85106369045

SN - 0016-5107

VL - 94

SP - 207-221.e14

JO - Gastrointestinal Endoscopy

JF - Gastrointestinal Endoscopy

IS - 2

ER -

ASGE guideline on the management of cholangitis

Abstract

Bibliographical note

PubMed: MeSH publication types

Publisher link

Find It

Other files and links

Fingerprint

Cite this